1800-272-662
Shopping Cart 0
countryflagAU
Login

Alterity Therapeutics Ltd

Healthcare AU ATH

0.008AUD
-(-%)

Last update at 2026-03-13T04:58:00Z

Day Range

0.0070.008
LowHigh

52 Week Range

0.0060.02
LowHigh

Fundamentals

  • Previous Close 0.008
  • Market Cap76.13M
  • Volume1415308
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-17.55062M
  • Revenue TTM6.64M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 6.47M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -12.07977M -19.07738M -13.70206M -12.77705M -15.30935M
Minority interest - - - - -
Net income -12.14783M -19.12346M -13.80651M -12.84706M -15.51999M
Selling general administrative 5.48M 4.77M 4.94M 5.46M 6.86M
Selling and marketing expenses - -0.00967M 0.05M - -
Gross profit 5.31M 3.80M 3.63M - -
Reconciled depreciation 0.14M 0.15M 0.10M 0.05M 0.08M
Ebit -14.66155M -19.60695M -15.28798M -17.85975M -14.50738M
Ebitda -14.63324M -19.45942M -15.18572M -17.80554M -14.43201M
Depreciation and amortization 0.03M 0.15M 0.10M 0.05M 0.08M
Non operating income net other - - - - -
Operating income -14.57429M -19.60171M -14.63614M -17.85975M -14.50738M
Other operating expenses 20.01M 23.62M 14.35M 15.14M 14.74M
Interest expense - - - 0.00250M 0.00000M
Tax provision 0.07M 0.05M 0.10M 0.07M 0.00000M
Interest income 0.45M 0.27M 0.02M 0.00250M 0.02M
Net interest income 0.45M 0.27M 0.02M 0.00250M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.05M 0.10M 0.07M 0.21M
Total revenue 5.44M 4.02M 3.92M 0.00250M 0.02M
Total operating expenses 19.89M 23.41M 14.35M 15.14M 14.74M
Cost of revenue 0.13M 0.21M 0.29M - -
Total other income expense net 2.49M 0.52M 0.65M 5.08M -0.80197M
Discontinued operations - - - - -
Net income from continuing ops -12.14783M -19.12346M -13.80651M -12.84706M -15.30935M
Net income applicable to common shares -12.14783M -19.12346M -13.80652M -12.84706M -15.30935M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 46.03M 19.22M 27.32M 41.36M 33.59M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.04M 2.36M 0.04M 0.01M 0.00936M
Total liab 3.62M 5.43M 4.50M 5.89M 3.12M
Total stockholder equity 42.40M 13.80M 22.81M 35.47M 30.47M
Deferred long term liab - - - - -
Other current liab 0.00014M 4.67M 2.67M -0.02692M 1.62M
Common stock - 223.15M 213.97M 213.79M 197.45M
Capital stock 262.95M - 213.97M 213.79M 197.45M
Retained earnings -225.88868M -214.16113M -195.13089M -181.88439M -169.72841M
Other liab - - 0.02M 0.01M 0.00977M
Good will - - - - -
Other assets - 0.00000M - - -
Cash 33.16M 12.64M 15.77M 34.81M 28.12M
Cash and equivalents - - - 34.81M 28.12M
Total current liabilities 3.53M 5.37M 4.38M 5.82M 3.07M
Current deferred revenue - 0.02M -0.10718M 3.10M -0.02775M
Net debt - -12.47984M -15.56340M -34.68931M -28.04987M
Short term debt - 0.11M 0.11M 0.06M 0.03M
Short long term debt - - - - -
Short long term debt total - 0.16M 0.21M 0.12M 0.07M
Other stockholder equity - - -18.84043M -31.90267M -27.71958M
Property plant equipment - - 0.27M 0.22M 0.10M
Total current assets 45.87M 19.04M 27.05M 41.14M 33.49M
Long term investments - - - - -
Net tangible assets - - 22.81M 35.47M 30.47M
Short term investments 7.50M - - - -
Net receivables - 4.04M 8.67M 4.73M 4.28M
Long term debt - - - - -
Inventory - 0.00000M 2.57M 1.60M 1.09M
Accounts payable 0.54M 0.58M 1.72M 2.69M 1.45M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 4.81M - 3.57M 2.75M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M -0.26886M -0.21852M -0.09681M
Deferred long term asset charges - - - - -
Non current assets total 0.16M 0.19M 0.27M 0.22M 0.10M
Capital lease obligations 0.16M - 0.21M 0.12M 0.07M
Long term debt total - - - 0.06M 0.04M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -7.50000M -0.00572M -0.00500M -0.08900M -0.00300M
Change to liabilities - - -1.56087M 2.60M 0.43M
Total cashflows from investing activities -7.50000M -0.00572M -0.03646M -0.08915M -0.01047M
Net borrowings -0.12710M -0.01037M -0.05992M -0.03451M -0.05829M
Total cash from financing activities 39.67M 9.22M 0.12M 16.30M 36.69M
Change to operating activities - - -0.88952M -0.39329M -0.62403M
Net income -12.14783M -19.12346M -13.80651M -12.84706M -15.30935M
Change in cash 20.52M -3.13490M -19.03302M 6.69M 18.92M
Begin period cash flow 12.64M 15.77M 34.81M 28.12M 9.20M
End period cash flow 33.16M 12.64M 15.77M 34.81M 28.12M
Total cash from operating activities -11.45125M -12.60582M -20.03584M -12.33727M -17.33007M
Issuance of capital stock 42.57M 10.14M 0.31M 17.18M 39.24M
Depreciation 0.14M 0.15M 0.10M 0.05M 0.08M
Other cashflows from investing activities -7.50000M 0.00000M -0.02915M -0.02915M -0.02915M
Dividends paid - - 0.00000M 0.00000M 0.00000M
Change to inventory - - 2.45M -2.21071M 0.19M
Change to account receivables 0.10M 4.62M -3.94034M -0.44768M -4.21636M
Sale purchase of stock 42.57M 10.14M 0.32M 17.18M 39.24M
Other cashflows from financing activities -2.77417M -0.91802M -0.13241M -0.83697M -2.49265M
Change to netincome - - 0.06M -1.30745M 2.31M
Capital expenditures 0.00000M 0.00572M 0.00731M 0.09M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.61368M 5.75M -3.94034M -0.44768M -4.21636M
Stock based compensation 0.98M 0.88M 0.97M 1.51M 1.88M
Other non cash items 0.19M -0.26115M -6.34873M 0.46M -2.09608M
Free cash flow -11.45125M -12.61155M -20.04315M -12.42642M -17.34054M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATH
Alterity Therapeutics Ltd		 - -% 0.008 - 10.33 11.47 1.60 164.75 1.13
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Alterity Therapeutics Ltd

350 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Geoffrey Paul Kempler B.Sc, B.Sc. Co-Founder & Non-Exec. Chairman 1955
Dr. David A. Stamler M.D. Chief Exec. Officer 1961
Ms. Kathryn J. E. Andrews Chief Financial Officer 1967
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of R&D Advisory Board 1958
Dr. Steven D. Targum Chief Medical Advisor NA
Dr. Robert Cherny Head of Research NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA Company Sec. 1959
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 1955
Dr. David A. Stamler M.D. Chief Executive Officer 1961
Ms. Kathryn J. E. Andrews B.Com, CPA Chief Financial Officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.